Navigation Links
ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
Date:3/23/2009

ATHENS, Ga., March 23 /PRNewswire/ -- ArunA Biomedical, Inc., announced today an agreement with Neuromics, Inc. of Edina, MN, giving Neuromics the right to non-exclusively market and sell the ArunA hN2(TM) Human Neural Cells and Neural Culture Medium to support applications in neurological research.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )

ArunA has an exclusive worldwide license to develop and commercialize neural cells derived from human embryonic stem cells (hESC), and hN2 is a second generation product from this technology. These cells offer a consistent population of normal human neural cells that the neural research and pharmaceutical market highly desires.

"ArunA has further developed its adherent monolayer technology by creating hN2(TM), a normal human neural cell ideal for drug screening, toxicology studies and basic neural research, and we are pleased to have Neuromics as a distribution partner," said David Ray, Chief Executive Officer of ArunA Biomedical.

"Neuromics growth is catalyzed by offering the unique products and expertise our customers require for research success through strategic alliances with companies like ArunA Biomedical. This relationship represents a growth opportunity for us. Their hN2(TM) cells fill a stated research need of the Neuroscience Community and we look forward to our customers having these cells and the related new discoveries they will help generate," said Pete Shuster, CEO and Owner of Neuromics.

Founded in 2003, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and neuroscience research.

Founded in 2003, Neuromics is a privately held Bio-regents Company focusing on providing research ready and proven products and methods expertise to Neuroscience, Diabetes/Obesity, Immunology and Researchers.

This press release contains forward-looking statements regarding the company's potential impact on scientific research and collaborations with third parties. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.

www.arunabiomedical.com


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
4. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
5. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... , ... Kablooe Design, a leading provider of product design and development services ... the business. “We have worked hard to build long-term relationships,” says President and CEO, ... honor of serving their product design and development needs through the years.” , Kablooe ...
(Date:5/19/2016)... RIDGE, British Columbia , May 19, 2016 ... AdvanTec Global Innovations Inc. (AGI), based out of ... recently added Greenlane Biogas Ltd. to its existing ... 2-year contract manufacturing agreement. AFS along with its ... Technologies (ABT) is a vertically integrated industrial group ...
(Date:5/19/2016)... -- - I dati saranno presentati nel ... ° Congresso della Società Americana ... - Le conclusioni dello studio indicano un tasso di risposta ... il 90% presenta una d urata della risposta (Duration ... per cento dei pazienti ha riscontrato un beneficio clinico. ...
(Date:5/18/2016)... ... May 18, 2016 , ... STACS DNA Inc., the sample tracking software ... report sexual assault kit processing to help them save time and reduce errors. , ... kits to be processed and victims informed of results. Due to a previous lack ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/21/2016)... 22, 2016 Unique technology ... for superior security   Xura, ... of secure digital communications services, today announced it is ... offer enterprise customers, particularly those in the Financial Services ... voice authentication within a mobile app, alongside, and in ...
Breaking Biology News(10 mins):